NCT03519113View on ClinicalTrials.gov

HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

March 31, 2022

Study Completion Date

September 30, 2022

Conditions
Hepatitis B Infection
Interventions
BIOLOGICAL

GC1102 80,000 IU

recombinant human hepatitis B immunoglobulin

BIOLOGICAL

GC1102 100,000 IU

recombinant human hepatitis B immunoglobulin

BIOLOGICAL

I.V HBIG

human anti-hepatitis B Immunoglobulin

Trial Locations (1)

Unknown

Seoul Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY

NCT03519113 - HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 | Biotech Hunter | Biotech Hunter